Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.65 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | IDO1 | P14902 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MTOR | P42345 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 8/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9004825 | 0.98 | RAB9A (0.63) | RAB9AMEN1KMT2AIDO1ALDH1A1 | |
| SCHEMBL27193042 | 0.88 | RAB9A (0.79) | RAB9AMEN1KMT2AMTORTAAR1 | |
| SCHEMBL30851500 | 0.88 | RAB9A (0.79) | RAB9AMEN1KMT2AMTORTAAR1 | |
| SCHEMBL27766670 | 0.83 | RAB9A (0.67) | RAB9AMEN1KMT2AMTORTAAR1 | |
| SCHEMBL4555389 | 0.83 | KMT2A (0.72) | RAB9AMEN1KMT2AMTORTAAR1 | |
| SCHEMBL27877501 | 0.82 | DDX3X (0.79) | RAB9AMEN1KMT2AALDH1A1MTOR | |
| SCHEMBL5634415 | 0.81 | RAB9A (0.65) | RAB9AMEN1KMT2AMTORTAAR1 | |
| SCHEMBL16480211 | 0.81 | RAB9A (0.65) | RAB9AMEN1KMT2AMTORTAAR1 | |
| SCHEMBL167713 | 0.81 | MEN1 (0.67) | RAB9AMEN1KMT2AIDO1ALDH1A1 | |
| SCHEMBL19027043 | 0.81 | KMT2A (0.83) | RAB9AMEN1KMT2AIDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| EP-1828124-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063863-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-06-22 | — | — | WO | disclosed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
| EP-0566445-B1 | Derivatives of indane 1,3-dione and indane-1,2,3-trione, processes for their preparation and their application in therapy | INNOTHERA LAB SA (FR) | 1996-02-07 | — | — | EP | disclosed |
| EP-0566445-A1 | Derivatives of indane 1,3-dione and indane-1,2,3-trione, processes for their preparation and their application in therapy | INNOTHERA (FR) | 1993-10-20 | — | — | EP | disclosed |
| WO-1993020045-A1 | INDAN-1,3-DIONE AND INDAN-1,2,3-TRIONE DERIVATIVES, PROCESSES FOR THE PREPARATION OF SAME AND THEIR APPLICATION AS THERAPEUTIC AGENTS | INNOTHERA (FR) | 1993-10-14 | — | — | WO | disclosed |
| US-5098462-A | Herbicides | SANDOZ LTD. (CH) | 1992-03-24 | — | — | US | disclosed |
| US-5098466-A | Herbicides | SANDOZ LTD. (CH) | 1992-03-24 | — | — | US | disclosed |
| EP-0219451-B1 | SEMICARBAZONES AND THIOSEMICARBAZONES | SANDOZ AG (CH) | 1991-03-20 | — | — | EP | disclosed |
| EP-0258182-A1 | Semicarbazones and thiosemicarbazones | SANDOZ AG (CH) | 1988-03-02 | — | — | EP | disclosed |
| EP-0219451-A1 | Semicarbazones and thiosemicarbazones | SANDOZ AG (CH) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | RAB9A 2314/4885MEN1 846/4885KMT2A 648/4885 |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | RAB9A 1997/4885MEN1 4750/4885KMT2A 3299/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | RAB9A 2314/4885MEN1 846/4885KMT2A 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.